|
Coronary Aneurysm
|
0.010 |
Biomarker
|
disease |
BEFREE |
The vWF:Collagen binding activity/vWF:Antigen ratio, however, was significantly decreased in patients with a coronary artery lesion (z-score > 2; N = 10; mean ratio 0.96 vs. 0.64; p = 0.031) and even more so in those with a coronary artery aneurysm (z-score > 2.5; N = 8; mean ratio 0.94 vs. 0.55; p = 0.02).
|
31760507 |
2020 |
|
Disseminated Intravascular Coagulation
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In patients with S. aureus bloodstream infections, high VWF levels and low ADAMTS13 activity levels correlated with disease severity and with parameters of inflammation and disseminated intravascular coagulation (DIC).
|
31758651 |
2020 |
|
Hepatic necrosis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
VWF plasma levels were measured by ELISA, and liver necrosis or hepatocyte proliferation was measured by immunohistochemistry.
|
31606553 |
2020 |
|
Inflammatory disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
The association of Kawasaki disease, a vascular inflammatory disease and vWF:Antigen, vWF:Collagen binding activity, and vWF multimers is unknown.
|
31760507 |
2020 |
|
Mirror syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Notably, we elucidated a temporal spectrum of maternal serum mediators (soluble Flt-1, endothelin-1, 8-isoprostane, activin-A, ICAM-1, and vWF) involved in the pathogenesis of Mirror syndrome.
|
30614331 |
2020 |
|
Congenital adrenal hyperplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In particular, non-random occurrence was revealed for SERPINA1 c.1096G > A (alpha-1 antitrypsin deficiency), C8B c.1282C > T and c.1653G > A (complement component 8B deficiency), ATP7B c.3207C > A (Wilson disease), PROP1 c.301_302delAG (combined pituitary hormone deficiency), CYP21A2 c.844G > T (non-classical form of adrenogenital syndrome), EYS c.1155T > A (retinitis pigmentosa), HADHA c.1528G > C (LCHAD deficiency), SCO2 c.418G > A (cytochrome c oxidase deficiency), OTOA c.2359G > T (sensorineural deafness), C2 c.839_866del (complement component 2 deficiency), ACADVL c.848T > C (VLCAD deficiency), TGM5 c.337G > T (acral peeling skin syndrome) and VWF c.2561 G > A (von Willebrand disease, type 2N).
|
31028847 |
2019 |
|
Anemia of chronic disease
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In the present review, we focus on aptamers as potential therapeutics for hematological diseases, including anemia of chronic inflammation (ACI) and anemia of chronic disease (ACD), hemophilia, thrombotic thrombocytopenic purpura (TTP) or VWD type-2B, and sickle cell disease (SCD), in particular, those that have entered into clinical trials.
|
28969551 |
2019 |
|
Angina, Unstable
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Serum PTX-3, vWf and CXCL13 levels were significantly higher in USAP group than those in either SAP or control groups (p˂0.001).
|
31066256 |
2019 |
|
Fabry Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that GLA deficiency promotes VWF secretion through eNOS dysregulation, which may contribute to the vasculopathy of Fabry disease.
|
30470436 |
2019 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, interleukin (IL)-1β and vascular endothelial growth factor (VEGF) levels were reduced, and fewer von Willebrand factor (vWF)-stained areas were identified in the fullerenol-treated joints than in control joints.The i.a. injection of fullerenol for reducing ROS production can ameliorate arthritis in joints by suppressing pro-inflammatory cytokine production and the angiogenesis process.Thus, the i.a. injection of fullerenol for reducing the production of ROS can be used as a pharmacological approach for RA patients.
|
31234583 |
2019 |
|
Febrile Convulsions
|
0.010 |
Biomarker
|
disease |
BEFREE |
Increased von Willebrand factor parameters in children with febrile seizures.
|
30605489 |
2019 |
|
Dementia, Vascular
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In contrast, the VD group showed increased fibrinogen levels (SMD: 0.77; 95% CI: 0.13-1.41), activated factor VII (SMD: 0.36; 95% CI: 0.05-0.67), factor VIII (SMD: 0.57; 95% CI: 0.22-0.91), VWF (SMD: 2.34; 95% CI: 0.38-4.29), D-dimer (SMD: 1.14; 95% CI: 0.51-1.78), and homocysteine (SMD: 2.17; 95% CI: 1.67-2.68).
|
31096308 |
2019 |
|
Dengue Fever
|
0.010 |
Biomarker
|
disease |
BEFREE |
Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of platelet clearance in dengue.
|
30849118 |
2019 |
|
Patent ductus arteriosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Five decreased proteins (platelet factor 4, fibrinogen, von Willebrand factor, collagen, and mannose binding lectin-associated serine protease-2) and one increased protein (fibronectin) may increase the risk of patent ductus arteriosus.
|
30480800 |
2019 |
|
Esophageal Varices
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Levels of vEF were correlated positively with esophageal varices grade.
|
30281535 |
2019 |
|
Gastric Varix
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> The results of impedance aggregometry, von Willebrand factor antigen level and thromboelastometry (TEM) with and without the addition of a platelet inhibitor (FIBTEM<sup>®</sup>, EXTEM<sup>®</sup> test, respectively) were compared in two patient groups: Group 1 (<i>n</i> = 32) - patients with moderate or large esophageal or gastric varices, who had never had symptoms of acute gastrointestinal bleeding and Group 2 (<i>n</i> = 26) - patients with history of variceal bleeding.
|
30907172 |
2019 |
|
Glaucoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Proper hematological investigations before glaucoma surgery in the left eye revealed a low level of factor VIII with normal levels of factor IX and von Willebrand's factor antigen.
|
30938185 |
2019 |
|
Hallucinations
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We used biochemical methods to assess microvessel density (level of von Willebrand factor, a marker of endothelial cell content), ante-mortem oxygenation (vascular endothelial growth factor, a marker of tissue hypoxia; myelin-associated glycoprotein to proteolipid protein-1 ratio, a measure of tissue oxygenation relative to metabolic demand), cholinergic innervation (acetylcholinesterase and choline acetyltransferase), butyrylcholinesterase and insoluble α-synuclein content in the BA18 and BA19 occipital cortex obtained post-mortem from 23 AD patients who had experienced visual hallucinations, 19 AD patients without hallucinations, 19 DLB patients, and 36 controls.
|
31511061 |
2019 |
|
Sensorineural Hearing Loss (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In particular, non-random occurrence was revealed for SERPINA1 c.1096G > A (alpha-1 antitrypsin deficiency), C8B c.1282C > T and c.1653G > A (complement component 8B deficiency), ATP7B c.3207C > A (Wilson disease), PROP1 c.301_302delAG (combined pituitary hormone deficiency), CYP21A2 c.844G > T (non-classical form of adrenogenital syndrome), EYS c.1155T > A (retinitis pigmentosa), HADHA c.1528G > C (LCHAD deficiency), SCO2 c.418G > A (cytochrome c oxidase deficiency), OTOA c.2359G > T (sensorineural deafness), C2 c.839_866del (complement component 2 deficiency), ACADVL c.848T > C (VLCAD deficiency), TGM5 c.337G > T (acral peeling skin syndrome) and VWF c.2561 G > A (von Willebrand disease, type 2N).
|
31028847 |
2019 |
|
Kidney Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
To test this hypothesis, we studied the role of VWF in AKI using a mouse model of acute ischemia-reperfusion (I/R) kidney injury.
|
31594992 |
2019 |
|
Waldenstrom Macroglobulinemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Considering vWF and ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) as markers of endothelial dysfunction and activation, we evaluated the prognostic importance of vWF and ADAMTS-13 antigen levels in the serum of patients with previously untreated symptomatic WM to validate vWF as a possible prognostic marker for progression-free and overall survival.
|
30224328 |
2019 |
|
Marfan Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In MFS von Willebrand factor (VWF) activity (81.9%±41.8% <i>vs.</i> 106.3%±41.5%, P<0.05) and antigen (93.8%±43.9% <i>vs.</i> 118.8%±47.8%, P<0.05) and factor VIII activity (108.9%±29.6% <i>vs.</i> 126.7%±28.4%, P<0.05) were reduced.
|
31737529 |
2019 |
|
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to measure the concentrations of serum levels of vascular endothelial growth factor, D-dimer, and von Willebrand factor in patients with newly diagnosed or relapsed multiple myeloma before treatment, during therapy, and after successful therapy.
|
30845824 |
2019 |
|
Peripheral Vascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Endothelial surface and circulating glycoprotein von Willebrand factor (vWF) regulates platelet adhesion and is associated with thrombotic diseases, including ischemic stroke, myocardial infarction, and peripheral vascular disease.
|
30987839 |
2019 |
|
Complete atrioventricular block
|
0.010 |
Biomarker
|
disease |
BEFREE |
ETV treatment resulted in an increased ADAMTS13: AC and decreased VWF: Ag (both P < 0.001) in CHB patients.
|
30976044 |
2019 |